Evidence map›Paper›PMID 39203953›Full record

ArticleVaccines2024

Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18-49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study.

Yanxia Wang, Gang Shi, Xue Wang, Zhiqiang Xie, Jinbo Gou, Lili Huang, Haitao Huang, Wangyang You, Ruijie Wang, Yongli Yang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  2. Article
  3. Pneumococcal vaccines in China.Human vaccines & immunotherapeutics · 2025
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yanxia WangHenan Center for Disease Control and Prevention, Zhengzhou 450016, China.
Gang ShiNational Institutes for Food and Drug Control, Beijing 100050, China.
Xue WangCanSino Biologics Inc., Tianjin 300457, China.
Zhiqiang XieHenan Center for Disease Control and Prevention, Zhengzhou 450016, China.
Jinbo GouCanSino Biologics Inc., Tianjin 300457, China.
Lili HuangHenan Center for Disease Control and Prevention, Zhengzhou 450016, China.
Haitao HuangCanSino Biologics Inc., Tianjin 300457, China.
Wangyang YouHenan Center for Disease Control and Prevention, Zhengzhou 450016, China.
Ruijie WangCanSino Biologics Inc., Tianjin 300457, China.
Yongli YangDepartment of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
Feiyu WangCanSino Biologics Inc., Tianjin 300457, China.
Tao ZhuCanSino Biologics Inc., Tianjin 300457, China.
Dongyang ZhaoHenan Center for Disease Control and Prevention, Zhengzhou 450016, China.

Funding

construction project of medical technology research and development plan of Henan province LHGJ20210135
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

immunogenicitypneumococcal surface protein Apneumolysin proteinprotein-based pneumococcal vaccine

Identifiers

PMID39203953
PMCPMC11358999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.